{"id":"NCT02046564","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder","officialTitle":"A Multicenter, Randomized, Double-blind Trial to Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-02","primaryCompletion":"2016-09","completion":"2016-09","firstPosted":"2014-01-28","resultsPosted":"2018-05-21","lastUpdate":"2018-05-21"},"enrollment":412,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"ASC-01","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"ASC-01","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate the efficacy and the safety of ASC-01 (aripiprazole/sertraline combination) compared to sertraline monotherapy in patients with major depressive disorders who have responded incompletely to sertraline monotherapy.","primaryOutcome":{"measure":"The Mean Change From Baseline in the Montgomery-Ã…sberg Depression Rating Scale (MADRS) Total Score","timeFrame":"8 weeks after the start of the sertraline treatment period (Baseline), 6 weeks after the start of the double-blind period (Last Observation Carried Forward [LOCF])","effectByArm":[{"arm":"ASC-01","deltaMin":-9.2,"sd":0.5},{"arm":"Placebo","deltaMin":-7.2,"sd":0.5}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":10},"locations":{"siteCount":29,"countries":["Australia","Japan","Malaysia","South Korea","Taiwan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":209},"commonTop":["Nasopharyngitis","Akathisia","Tremor","Headache","Dizziness"]}}